Imfinzi + Imjudo approved in advanced liver cancer
24 October 2022 07:00 BST Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib AstraZeneca's Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer. The novel dose and schedule of the combination, which includes